China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

Namasthe
Find the healthcare and drug approval news of India, China, Japan, Australia and other Asian countries




China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter


China Healthcare News | Drug News | iPharmaCenter


Drug approvals in Japan | PMDA | MHLW Approvals | 2022 | 2023 | News | Media | Japan | iPharmaCenter


India | Healthcare News | Abbott to upgrade 75 PHCs | iPharmaCenter


Australia Healthcare News | Drug reimbursement


Australia Drug Approvals | Drugs approved by TGA


COVID-19 India Updates | Covaxin approved for children | Vaccines for teenagers


China released the 2022 NDRL list, Chinese pharma benefited from the list


Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief


WHO granted EUL to Covaxin; acclaims easy storage requirement


Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System


Expected best selling pharmaceutical products (drugs) in 2021


Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Bayer submitted vericiguat for market authorization in China


Bayer’s Xofigo received approval for prostate cancer in China


Merck’s Keytruda received one more indication and dosage form approval in Japan


AZ received one more approval in Japan, received approval of Imfinzi for SCLC


JAPAN HEALTHCARE SYSTEM
China’s National Medicinal Products Administration approved Gilead’s Truvada
Eisai's Dayvigo was approved in Japan and Hong Kong for insomnia
Merck’s Keytruda approved in China for esophageal squamous cell carcinoma
GSK and Clover Biopharmaceuticals begins COVID-19 vaccine Phase 1 clinical trial


May witnessed the approval of Pfizer’s Talzenna, Nyprax’s Tukysa, Drug Houses’ Ajovy in Singapore
Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients